Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
2.
Article in English | MEDLINE | ID: mdl-32745814

ABSTRACT

OBJECTIVE: Intraoperative specimen mammography (ISM) is a diffuse technique that allows surgeons to check specimens immediately after lumpectomy. Although the specimen is slightly compressed, the radiological image can be distorted by tissue overlap, and this may affect the evaluation of tumour borders, resulting in extension of the lumpectomy. As ISM may be less precise due to inadequate compression, a vacuum effect was applied to the specimen to increase the precision of margin detection. STUDY DESIGN: This study was conducted at St. Anna Hospital Breast Unit, Turin, Italy. Women who underwent lumpectomy for cancer were eligible for inclusion. Both standard ISM (sISM) and vacuum ISM (vISM) were performed. Eighteen specimens obtained after lumpectomy from 1 April 2018 to 31 April 2018 were scanned. sISM (two orthogonal projections) was performed. Next, the specimen was placed in a vacuum, and vISM was performed. The examination was completed with a second orthogonal projection after removal of the vacuum, replacement of the specimen and repositioning of the vacuum. Additional tissue was removed if the surgeon considered that excision was inadequate. Finally, the specimen was sent for definitive histopathological analysis, which is the gold standard for the assessment of surgical margins. Intraoperative histological margin assessment was not performed. The sISM and vISM images and final histopathology reports were compared. RESULTS: For sISM, specificity was 47 % [95 % confidence interval (CI) 25-70], sensitivity was 67 % (95 % CI 21-94), positive predictive value (PPV) was 20 % (95 % CI 6-51) and negative predictive value (NPV) was 88 % (95 % CI 53-98). For vISM, specificity was 100 % (95 % CI 80-100), sensitivity was 67 % (95 % CI 21-94), PPV was 100 % (95 % CI 34-100) and NPV was 94 % (95 % CI 72-99). CONCLUSION: These data suggest that the vacuum technique is feasible, cost-saving and yields results that are similar to those from frozen sections but without the limitations, such as prolonged operating time, high variability in sensitivity due to pathologists' abilities, risk of compromising the histological report, and unreliability for small lumps and ductal carcinoma in situ.


Subject(s)
Breast Neoplasms , Mastectomy, Segmental , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/surgery , Female , Humans , Italy , Mammography , Vacuum
3.
In Vivo ; 34(2): 909-915, 2020.
Article in English | MEDLINE | ID: mdl-32111803

ABSTRACT

BACKGROUND/AIM: The aim of the study was to evaluate whether residual tumor assessment by magnetic resonance imaging (MRI) after neoadjuvant chemotherapy (NACT) is fundamental for a successive surgical strategy. PATIENTS AND METHODS: We collected 55 MRIs performed after NACT. RESULTS: Pathological response rate was 20%. MRI's sensitivity, specificity, PPV and NPV were 50%, 88%, 54% and 86%, respectively. We observed a high variability between the different subgroups, with high number of false positives in luminal A/B tumors. Triple negative and HER2+ tumors had almost the same specificity and sensitivity (81% and 50%). Nevertheless, in the HER2+ group, PPV was greater than that in the triple negative group (71% and 33% respectively) and the NPV of the triple negative group was greater than that of the HER2+ one (90% and 64%, respectively). Statistical analysis showed a weak but significant correlation between MRI and pathological assessment of residual tumor dimension. CONCLUSION: The present study, confirms literature data about MRI accuracy in diagnosing HER2+ and triple negative tumors, but suggests caution in case of luminal tumors' evaluation.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/drug therapy , Magnetic Resonance Imaging , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Tumor , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Clinical Decision-Making , Disease Management , Female , Humans , Magnetic Resonance Imaging/methods , Magnetic Resonance Imaging/standards , Neoadjuvant Therapy , Neoplasm Staging , Sensitivity and Specificity , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL